JP4806469B2 - ホルマリン固定およびパラフィン包埋された組織においてＭｅｔを結合するモノクローナル抗体および関連する方法 - Google Patents

ホルマリン固定およびパラフィン包埋された組織においてＭｅｔを結合するモノクローナル抗体および関連する方法 Download PDF

Info

Publication number
JP4806469B2
JP4806469B2 JP2010522103A JP2010522103A JP4806469B2 JP 4806469 B2 JP4806469 B2 JP 4806469B2 JP 2010522103 A JP2010522103 A JP 2010522103A JP 2010522103 A JP2010522103 A JP 2010522103A JP 4806469 B2 JP4806469 B2 JP 4806469B2
Authority
JP
Japan
Prior art keywords
met
antigen
met4
antibody
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010522103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536886A (ja
JP2010536886A5 (https=
Inventor
ボーリャン カオ，
ウォウド， ジョージ エフ． バンデ
ベアトリス エス． クヌードセン，
ピン スー チャオ，
Original Assignee
ヴァン アンデル リサーチ インスティテュート
フレッド ハッチンソン キャンサー リサーチ センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァン アンデル リサーチ インスティテュート, フレッド ハッチンソン キャンサー リサーチ センター filed Critical ヴァン アンデル リサーチ インスティテュート
Publication of JP2010536886A publication Critical patent/JP2010536886A/ja
Publication of JP2010536886A5 publication Critical patent/JP2010536886A5/ja
Application granted granted Critical
Publication of JP4806469B2 publication Critical patent/JP4806469B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2010522103A 2007-08-24 2008-08-25 ホルマリン固定およびパラフィン包埋された組織においてＭｅｔを結合するモノクローナル抗体および関連する方法 Expired - Fee Related JP4806469B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/845,023 US7892770B2 (en) 2007-08-24 2007-08-24 Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
US11/845,023 2007-08-24
PCT/US2008/074249 WO2009029591A2 (en) 2007-08-24 2008-08-25 Monoclonal antibody which binds met in formalin-fixed and paraffin-embedded tissues and related methods

Publications (3)

Publication Number Publication Date
JP2010536886A JP2010536886A (ja) 2010-12-02
JP2010536886A5 JP2010536886A5 (https=) 2011-06-30
JP4806469B2 true JP4806469B2 (ja) 2011-11-02

Family

ID=40193999

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010522103A Expired - Fee Related JP4806469B2 (ja) 2007-08-24 2008-08-25 ホルマリン固定およびパラフィン包埋された組織においてＭｅｔを結合するモノクローナル抗体および関連する方法

Country Status (6)

Country Link
US (2) US7892770B2 (https=)
EP (1) EP2195345B1 (https=)
JP (1) JP4806469B2 (https=)
CA (1) CA2715103C (https=)
ES (1) ES2386188T3 (https=)
WO (1) WO2009029591A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365421A1 (en) 2001-07-10 2003-09-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of the multiple proteins in single cells
EP2261650A3 (en) * 2004-09-15 2011-07-06 IntegenX Inc. Microfluidic devices
US7892770B2 (en) * 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2011261161A1 (en) * 2010-06-01 2013-01-10 Ludwig Institute For Cancer Research Limited Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
EP2402370A1 (en) * 2010-06-29 2012-01-04 Pierre Fabre Médicament Novel antibody for the diagnosis and/or prognosis of cancer
EP2635602B1 (en) 2010-11-03 2016-09-07 Argen-X Nv Anti c-met antibodies
US20140348819A1 (en) 2011-06-24 2014-11-27 Dana-Farber Cancer Institute, Inc. Methods of Treating Cancer
CA2843771A1 (en) * 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
EP3560509B1 (en) 2011-12-22 2024-01-31 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
JP6129956B2 (ja) * 2012-05-09 2017-05-17 イーライ リリー アンド カンパニー 抗ｃ−Ｍｅｔ抗体
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
US10450376B2 (en) 2014-09-16 2019-10-22 Symphogen A/S Anti-MET antibodies and compositions
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
PE20230343A1 (es) 2015-12-11 2023-03-01 Immatics Biotechnologies Gmbh Peptidos que estimulan respuestas inmunitarias antitumorales
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
PH12022552076A1 (en) 2020-02-12 2023-11-29 Janssen Biotech Inc TREATMENT OF PATIENTS HAVING c-MET EXON 14 SKIPPING MUTATIONS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917017A (en) * 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
NZ528205A (en) * 2001-03-12 2006-09-29 Monogen Inc Cell-based detection and differentiation of disease status in a cytological sample using a panel comprising a plurality of probes
US7892770B2 (en) * 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods

Also Published As

Publication number Publication date
US7892770B2 (en) 2011-02-22
WO2009029591A2 (en) 2009-03-05
ES2386188T3 (es) 2012-08-13
EP2195345A2 (en) 2010-06-16
CA2715103A1 (en) 2009-03-05
WO2009029591A3 (en) 2009-05-28
CA2715103C (en) 2013-10-15
EP2195345B1 (en) 2012-05-30
US20100285504A1 (en) 2010-11-11
US20090053737A1 (en) 2009-02-26
JP2010536886A (ja) 2010-12-02
US8309315B2 (en) 2012-11-13

Similar Documents

Publication Publication Date Title
JP4806469B2 (ja) ホルマリン固定およびパラフィン包埋された組織においてＭｅｔを結合するモノクローナル抗体および関連する方法
JP6636016B2 (ja) 抗ｂ７−ｈ３抗体及びその診断用途
RU2651513C2 (ru) Новое антитело для диагностики и (или) прогнозирования рака
JP6316348B2 (ja) Ｅｒｇモノクローナル抗体
KR102366820B1 (ko) 진단을 위한 세포 표면 전립선암 항원
CA3058263C (en) Compositions and methods for detecting prostate cancer
CN108700586A (zh) 用于评估癌症发生的风险的组合物和方法
KR20080106157A (ko) Ｆａｓ 결합 항체
RU2706967C2 (ru) Антитело к igf-1r и его применение для диагностики рака
RU2706959C2 (ru) Антитело к igf-1r и его применение для диагностики рака
CN115210256A (zh) 用于前列腺癌诊断的新方法和化合物
US20230340147A1 (en) Antibodies specific for alpha-1,6-core-fucosylated psa and fucosylated fragments thereof
JP4319700B1 (ja) 酸化修飾タンパク質またはポリペプチドに対する高特異性モノクローナル抗体
WO2022056329A1 (en) Snx9 subfamily-targeting antibodies
HK1183311A (en) Novel antibody for the diagnosis and/or prognosis of cancer
JP2003506021A (ja) リン酸化Ｍｅｔタンパク質と結合する抗体による悪性疾患の予後判定および治療
HK1248730B (zh) Igf-1r抗体及其用於癌症诊断的用途
HK1243434B (zh) Igf-1r抗体及其诊断癌症的用途
HK1169420A (en) Anti-cmet antibody and its use for the detection and the diagnosis of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110127

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20110127

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20110221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110225

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110513

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110714

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110812

R150 Certificate of patent or registration of utility model

Ref document number: 4806469

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140819

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees